Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Despite the availability of antiretroviral therapy (ART) that fully suppresses human immunodeficiency virus type-1 (HIV), markers of inflammation and minor neurocognitive impairment are frequently identified in HIV-infected persons. Increasing data support that low-level replication defective viral RNA is made by infected cells despite the absence of infectious virus. Specific GU-rich single-stranded RNA from the HIV long terminal repeat region (ssRNA40) signaling through toll-like receptor (TLR)-7 and -8 has been shown to induce the secretion of interleukin-1β (IL-1β) in primary monocytes. Here, we examined the activation of microglial cells by HIV ssRNA40 and the potential subsequent neurotoxicity. Our findings show that exposure of human primary microglia to ssRNA40 activates the NLR family pyrin domain containing 3 (NLRP3) inflammasome. Following exposure to ssRNA40, pro-inflammatory cytokines IL-1β, IL-18, and neurotoxic cytokines TNF-α, IL-1α, and C1q expression and extracellular secretion are increased. The released cytokines are functional since culture supernatants from ssRNA40 exposed microglia-induced toxicity of human primary neurons. Moreover, inflammasome activation of microglia increased ROS generation with a loss of mitochondrial membrane potential and mitochondrial integrity. Treatment with ssRNA40 resulted in a blockade of autophagy/mitophagy mediated negative regulation of NLRP3 inflammasome activity with the release of inflammatory cytokines, caspase-1 activation, and pyroptotic microglial cell death. Thus, HIV ssRNA mediated activation of microglial cells can contribute to neurotoxicity and neurodegeneration via secretion of inflammatory and neurotoxic cytokines. These findings provide a potential mechanism that explains the frequent minor cognitive deficits and chronic inflammation that persist in HIV-infected persons despite treatment with suppressive ART.
Pubmed ID: 30582668
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets Tom20 (FL-145)
View all literature mentionsThis monoclonal targets SQSTM1 / p62
View all literature mentionsThis monoclonal targets Phospho-TBK1/NAK (Ser172)
View all literature mentionsThis monoclonal targets Parkin
View all literature mentionsThis polyclonal targets Beclin 1
View all literature mentionsThis monoclonal targets beta-Actin
View all literature mentionsThis monoclonal targets Tbk1
View all literature mentionsThis monoclonal targets Human TOMM20
View all literature mentionsThis polyclonal targets Human Optineurin
View all literature mentionsThis polyclonal targets TNF
View all literature mentionsThis polyclonal targets Optineurin
View all literature mentionsThis polyclonal targets IL1 alpha
View all literature mentionsThis monoclonal targets NLRP3/NALP3
View all literature mentionsThis monoclonal targets Human TOMM20
View all literature mentionsThis monoclonal targets SQSTM1 / p62
View all literature mentionsThis polyclonal targets Human Optineurin
View all literature mentionsThis monoclonal targets Phospho-TBK1/NAK (Ser172)
View all literature mentionsThis monoclonal targets Tbk1
View all literature mentionsThis polyclonal targets Beclin 1
View all literature mentionsThis monoclonal targets beta-Actin
View all literature mentionsThis monoclonal targets NLRP3/NALP3
View all literature mentionsThis polyclonal targets Tom20 (FL-145)
View all literature mentionsThis polyclonal targets Optineurin
View all literature mentionsThis polyclonal targets IL1 alpha
View all literature mentionsThis polyclonal targets TNF
View all literature mentions